RDHL - Redhill Biopharma Ltd.

0.92
-0.026   -2.772%

Share volume: 14,517
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%
$0.95
-0.03
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 15%
Dept financing 11%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-2.13%
1 Month
-12.80%
3 Months
-23.33%
6 Months
-35.21%
1 Year
-69.54%
2 Year
67.33%
Key data
Stock price
$0.92
P/E Ratio 
0.00
DAY RANGE
$0.91 - $0.95
EPS 
-$1.53
52 WEEK RANGE
$0.88 - $3.31
52 WEEK CHANGE
-$69.54
MARKET CAP 
10.835 M
YIELD 
N/A
SHARES OUTSTANDING 
1.275 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-28-2025
BETA 
1.02
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$30,356
AVERAGE 30 VOLUME 
$45,077
Company detail
CEO: Dror Ben-Asher
Region: US
Website: redhillbio.com
Employees: 210
IPO year: 2013
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

RedHill Biopharma Ltd. primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections.

Recent news